Your browser doesn't support javascript.
loading
Identification of new DNA gyrase inhibitors based on bioactive compounds from streptomyces: structure-based virtual screening and molecular dynamics simulations approaches.
Kalhor, Hourieh; Sadeghi, Solmaz; Marashiyan, Mahya; Kalhor, Reyhaneh; Aghaei Gharehbolagh, Sanaz; Akbari Eidgahi, Mohammad Reza; Rahimi, Hamzeh.
Affiliation
  • Kalhor H; Department and Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Sadeghi S; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Marashiyan M; Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Kalhor R; Department of Biology, Qom Branch, Islamic Azad University, Qom, Iran.
  • Aghaei Gharehbolagh S; Department of Medical Mycology & Parasitology School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Akbari Eidgahi MR; Department and Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Rahimi H; Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
J Biomol Struct Dyn ; 38(3): 791-806, 2020 02.
Article in En | MEDLINE | ID: mdl-30916622
ABSTRACT
DNA gyrase enzyme has vital role in bacterial survival and can be considered as a potential drug target. Owing to the appearance of resistance to gyrase-targeted drugs, especially fluoroquinolone, screening new compounds which bind more efficiently to the mutant binding pocket is essential. Hence, in this work, using Smina Autodock and through structure-based virtual screening of StreptomeDB, several natural products were discovered based on the SimocyclinoneD8 (SD8) binding pocket of GyrA subunit of DNA gyrase. After evaluation of binding affinity, binding modes, critical interactions and physicochemical and pharmaceutical properties, three lead compounds were selected for further analysis. Afterward 60 ns molecular dynamics simulations were performed and binding free energies were calculated by the molecular mechanics/Poisson-Boltzmann surface area method. Also, interaction of the selected lead compounds with the mutated GyrA protein was evaluated. Results indicated that all of the selected compounds could bind to the both wild-type and mutated GyrA with the binding affinities remarkably higher than SimocyclinoneD8. Interestingly, we noticed that the selected compounds comprised angucycline moiety in their structure which could sufficiently interact with GyrA and block the DNA binding pocket of DNA gyrase, in silico. In conclusion, three DNA gyrase inhibitors were identified successfully which were highly capable of impeding DNA gyrase and can be considered as potential drug candidates for treatment of fluoroquinolone-resistant strains.Communicated by Ramaswamy H. Sarma.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Streptomyces / DNA Gyrase / Drug Evaluation, Preclinical / Molecular Dynamics Simulation / Topoisomerase II Inhibitors Type of study: Diagnostic_studies / Screening_studies Language: En Journal: J Biomol Struct Dyn Year: 2020 Type: Article Affiliation country: Iran

Full text: 1 Database: MEDLINE Main subject: Streptomyces / DNA Gyrase / Drug Evaluation, Preclinical / Molecular Dynamics Simulation / Topoisomerase II Inhibitors Type of study: Diagnostic_studies / Screening_studies Language: En Journal: J Biomol Struct Dyn Year: 2020 Type: Article Affiliation country: Iran